MedTrace Logo

Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study

NCT05281770 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1500

Last updated 2022-10-20

No results posted yet for this study

Summary

The present non-interventional study on migraine prevention with monoclonal CGRP antibodies adresses questions concering safety, swichting from one CGRP mab to another, efficacy on auras in the real world setting.

Conditions

  • Migraine
  • Migraine With Aura
  • Migraine Without Aura
  • Chronic Migraine
  • Episodic Migraine

Interventions

DRUG

Erenumab

treatment with erenumab as chosen by treating physician

DRUG

Fremanezumab

treatment with fremanezumab as chosen by treating physician

DRUG

Galcanezumab

treatment with galcanezumab as chosen by treating physician

Sponsors & Collaborators

  • Medical University of Vienna

    collaborator OTHER

  • Medical University Innsbruck

    collaborator OTHER

  • Austrian Headache Society

    collaborator UNKNOWN

  • Austrian Migraine Registry Collaboration

    lead NETWORK

Principal Investigators

  • Gregor Broessner, Prof · Medical University Innbruck

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-01
Primary Completion
2025-09-01
Completion
2025-12-01
FDA Drug
Yes

Countries

  • Austria

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05281770 on ClinicalTrials.gov